Calyx Therapeutics, Inc.
Records under this name other than patents Calyx Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Calyx Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,407,978 | Heterocyclic analogs of diphenylethylene compounds Formerly held Lapsed on the fee record Ended Aug 5, 2016 · USPTO record | Lapsed on the fee record | Ended Aug 5, 2016 | USPTO record |
| US 7,323,496 | Compounds for treatment of inflammation, diabetes and related disorders Formerly held Lapsed on the fee record Ended Jan 29, 2016 · USPTO record | Lapsed on the fee record | Ended Jan 29, 2016 | USPTO record |
| US 7,202,366 | Heterocyclic analogs of diphenylethylene compounds Formerly held Lapsed on the fee record Ended Apr 10, 2015 · USPTO record | Lapsed on the fee record | Ended Apr 10, 2015 | USPTO record |
| US 7,105,552 | Heterocyclic analogs of diphenylethylene compounds Formerly held Lapsed on the fee record Ended Sep 12, 2014 · USPTO record | Lapsed on the fee record | Ended Sep 12, 2014 | USPTO record |
| US 7,718,682 | Heterocyclic analogs of diphenylethylene compounds Formerly held Lapsed on the fee record Ended May 18, 2014 · USPTO record | Lapsed on the fee record | Ended May 18, 2014 | USPTO record |
| US 6,331,633 | Heterocyclic analogs of diphenylethylene compounds Formerly held Lapsed on the fee record Ended Dec 18, 2013 · USPTO record | Lapsed on the fee record | Ended Dec 18, 2013 | USPTO record |
| US 6,245,814 | Diphenylethylene compounds Formerly held Lapsed on the fee record Ended Jun 12, 2013 · USPTO record | Lapsed on the fee record | Ended Jun 12, 2013 | USPTO record |
| US 6,855,732 | Compounds to treat diabetes and associated conditions Formerly held Lapsed on the fee record Ended Feb 15, 2013 · USPTO record | Lapsed on the fee record | Ended Feb 15, 2013 | USPTO record |
| US 6,852,695 | Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes Formerly held Lapsed on the fee record Ended Feb 8, 2013 · USPTO record | Lapsed on the fee record | Ended Feb 8, 2013 | USPTO record |
| US 6,127,338 | Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes Formerly held Lapsed on the fee record Ended Oct 3, 2012 · USPTO record | Lapsed on the fee record | Ended Oct 3, 2012 | USPTO record |